KURA · Kura Oncology, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on KURA. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About KURA · Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Live Quote
BUY (score +7) · 12-1 mom 86.1% · RSI 62.8 · above_both · -14.5% from high
Targets blend Wall Street consensus (12 analysts: low $15.00 / mean $31.17 / high $76.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Stage crashed before producing an artifact (e.g. LM Studio timeout, malformed JSON, network error). The cooldown will hold this off the queue for ~1h before retry.